Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib vs Alectinib in ALK+ NSCLC
NCT03596866Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2019
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of brigatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Takeda. Primary endpoint: Progression-free Survival up to 33.8 months. Started Apr 2019; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03596866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596866.